BACKGROUND AND PURPOSE: Although previous animal studies have shown structural changes in ocular hypertension such as atrophy of the LGN, such changes have not been thoroughly studied in human glaucoma patients nor correlation made with clinical stage. Our aim was to investigate prospectively LGN atrophy in patients with POAG using 3T MR imaging and correlation with the clinical stage of disease. MATERIALS AND METHODS: Twenty-six patients with known POAG and 26 age-matched healthy volunteers were included in this institutional review board-approved study. All subjects underwent imaging on a 3T MR imaging system with a PD and GM sequence. LGN height and volume were measured by 2 blinded neuroradiologists. Measurements were compared and correlated with clinical glaucoma severity as assessed by static threshold visual field parameters. RESULTS: Average maximum LGN height in patients with glaucoma on PD images was 4.36 ± 0.61 mm (right) and 4.31 ± 0.61 mm (left), significantly less (P < 10⁻³) than respective measurements of 5.05 ± 0.41 and 4.99 ± 0.41 mm in volunteers. With the GM sequences, such respective measurements were also less (P < 10⁻³) in patients with glaucoma (4.20 ± 0.71 mm right, 4.00 ± 0.85 mm left) versus respective measurements in volunteers (4.88 ± 0.51 mm right, 4.77 ± 0.47 mm left). Average LGN volumes in the patient group were 98.0 ± 27.2 mm³ (right) and 93.7 ± 25.8 mm³ (left) with the PD sequence versus respective measurements of 85.2 ± 27.1 and 80.5 ± 23.6 mm³ with the GM sequence. All height and volume measurements were greater in volunteers (P < 10⁻³). In the patient group, both maximum height and volume of the LGN with both sequences were significantly correlated with cumulative clinical glaucoma stage (P < .05). CONCLUSIONS: MR imaging measurements of LGN height and volume are diminished in patients with glaucoma, with the extent of atrophy correlating to clinical stage, suggesting a novel imaging marker of disease severity.
BACKGROUND AND PURPOSE: Although previous animal studies have shown structural changes in ocular hypertension such as atrophy of the LGN, such changes have not been thoroughly studied in humanglaucomapatients nor correlation made with clinical stage. Our aim was to investigate prospectively LGN atrophy in patients with POAG using 3T MR imaging and correlation with the clinical stage of disease. MATERIALS AND METHODS: Twenty-six patients with known POAG and 26 age-matched healthy volunteers were included in this institutional review board-approved study. All subjects underwent imaging on a 3T MR imaging system with a PD and GM sequence. LGN height and volume were measured by 2 blinded neuroradiologists. Measurements were compared and correlated with clinical glaucoma severity as assessed by static threshold visual field parameters. RESULTS: Average maximum LGN height in patients with glaucoma on PD images was 4.36 ± 0.61 mm (right) and 4.31 ± 0.61 mm (left), significantly less (P < 10⁻³) than respective measurements of 5.05 ± 0.41 and 4.99 ± 0.41 mm in volunteers. With the GM sequences, such respective measurements were also less (P < 10⁻³) in patients with glaucoma (4.20 ± 0.71 mm right, 4.00 ± 0.85 mm left) versus respective measurements in volunteers (4.88 ± 0.51 mm right, 4.77 ± 0.47 mm left). Average LGN volumes in the patient group were 98.0 ± 27.2 mm³ (right) and 93.7 ± 25.8 mm³ (left) with the PD sequence versus respective measurements of 85.2 ± 27.1 and 80.5 ± 23.6 mm³ with the GM sequence. All height and volume measurements were greater in volunteers (P < 10⁻³). In the patient group, both maximum height and volume of the LGN with both sequences were significantly correlated with cumulative clinical glaucoma stage (P < .05). CONCLUSIONS: MR imaging measurements of LGN height and volume are diminished in patients with glaucoma, with the extent of atrophy correlating to clinical stage, suggesting a novel imaging marker of disease severity.
Authors: M Kitajima; T Hirai; T Yoneda; Y Iryo; M Azuma; M Tateishi; K Morita; M Komi; Y Yamashita Journal: AJNR Am J Neuroradiol Date: 2015-06-11 Impact factor: 3.825
Authors: Athina Papadopoulou; Laura Gaetano; Armanda Pfister; Anna Altermatt; Charidimos Tsagkas; Felix Morency; Alexander U Brandt; Martin Hardmeier; Mallar M Chakravarty; Maxime Descoteaux; Ludwig Kappos; Till Sprenger; Stefano Magon Journal: Neurology Date: 2019-04-10 Impact factor: 9.910
Authors: Larissa McKetton; Joy Williams; Joseph D Viviano; Yeni H Yücel; Neeru Gupta; Keith A Schneider Journal: J Vis Exp Date: 2015-12-30 Impact factor: 1.355
Authors: Unal Mutlu; Mohammad K Ikram; Gennady V Roshchupkin; Pieter W M Bonnemaijer; Johanna M Colijn; Johannes R Vingerling; Wiro J Niessen; Mohammad A Ikram; Caroline C W Klaver; Meike W Vernooij Journal: Hum Brain Mapp Date: 2018-06-23 Impact factor: 5.038
Authors: Jeffrey R Sims; Anna M Chen; Zhe Sun; Wenyu Deng; Nicole A Colwell; Max K Colbert; Jingyuan Zhu; Anoop Sainulabdeen; Muneeb A Faiq; Ji Won Bang; Kevin C Chan Journal: J Magn Reson Imaging Date: 2020-10-02 Impact factor: 4.813
Authors: Piotr Bogorodzki; Ewa Piątkowska-Janko; Jerzy Szaflik; Jacek Paweł Szaflik; Mira Gacek; Paweł Grieb Journal: PLoS One Date: 2014-04-07 Impact factor: 3.240